Search

Your search keyword '"Judit Sacanell"' showing total 4 results
Start Over Author "Judit Sacanell" Language english
4 results on '"Judit Sacanell"'

1. Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation.

Author

Cristina Berastegui, Susana Gómez-Ollés, Alberto Mendoza-Valderrey, Thais Pereira-Veiga, Mario Culebras, Victor Monforte, Berta Saez, Manuel López-Meseguer, Helena Sintes-Permanyer, Victoria Ruiz de Miguel, Carlos Bravo, Judit Sacanell, María-Antonia Ramon, Laura Romero, María Deu, and Antonio Román

Subjects
Medicine, Science
Abstract

KL-6 is an antigen produced mainly by damaged type II pneumocytes that is involved in interstitial lung disease. Chronic lung allograft dysfunction (CLAD) after lung transplantation (LT) is a major concern for LT clinicians, especially in patients with restrictive allograft syndrome (RAS). We investigated KL-6 levels in serum and bronchoalveolar lavage fluid (BALF) as a potential biomarker of the RAS phenotype. Levels of KL-6 in serum and BALF were measured in 73 bilateral LT recipients, and patients were categorized into 4 groups: stable (ST), infection (LTI), bronchiolitis obliterans syndrome (BOS), and RAS. We also studied a healthy cohort to determine reference values for serum KL-6. The highest levels of KL-6 were found in the serum of patients with RAS (918 [487.8-1638] U/mL). No differences were found for levels of KL-6 in BALF. Using a cut-off value of 465 U/mL serum KL-6 levels was able to differentiate RAS patients from BOS patients with a sensitivity of 100% and a specificity of 75%. Furthermore, higher serum KL-6 levels were associated with a decline in Forced Vital Capacity (FVC) at 6 months after sample collection. Therefore, KL-6 in serum may well be a potential biomarker for differentiating between the BOS and RAS phenotypes of CLAD in LT recipients.

Published
2020
Full Text
View/download PDF

2. Cardiac tamponade as a cause of cardiac arrest in severe COVID-19 pneumonia

Author

Eduard Argudo, Francesc Xavier Nuvials, Juan Carlos Ruiz-Rodríguez, Daniel Ruiz, Luis Chiscano-Camón, Judit Sacanell, and Ricard Ferrer

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Fatal outcome, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Disease progression, Emergency Nursing, medicine.disease, Article, Pneumonia, Cardiac tamponade, Internal medicine, Emergency, Pandemic, Emergency Medicine, medicine, Cardiology and Cardiovascular Medicine, business
Published
2020

3. Effects of an omega-3 fatty acid-enriched lipid emulsion on eicosanoid synthesis in acute respiratory distress syndrome (ARDS): A prospective, randomized, double-blind, parallel group study

Author

Pilar Sabin, Joan R. Masclans, Judit Sacanell, Pilar Chacón, Merce Planas, and Joan Sabater

Subjects
ARDS, Nutrition and Dietetics, Group study, business.industry, Research, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), lcsh:TX341-641, Biological activity, Clinical nutrition, Pharmacology, medicine.disease, lcsh:Nutritional diseases. Deficiency diseases, chemistry.chemical_compound, chemistry, Eicosanoid, Immunology, Medicine, Lipid emulsion, Arachidonic acid, lipids (amino acids, peptides, and proteins), Omega 3 fatty acid, business, lcsh:Nutrition. Foods and food supply, lcsh:RC620-627
Abstract

Background The use of lipid emulsions has been associated with changes in lung function and gas exchange which may be mediated by biologically active metabolites derived from arachidonic acid. The type and quantity of the lipid emulsions used could modulate this response, which is mediated by the eicosanoids. This study investigates the use of omega-3 fatty acid-enriched lipid emulsions in ARDS patients and their effects on eicosanoid values. Methods Prospective, randomized, double-blind, parallel group study carried out at the Intensive Medicine Department of Vall d'Hebron University Hospital (Barcelona-Spain). We studied 16 consecutive patients with ARDS and intolerance to enteral nutrition (14 men; age: 58 ± 13 years; APACHE II score 17.8 ± 2.3; Lung Injury Score: 3.1 ± 0.5; baseline PaO2/FiO2 ratio: 149 ± 40). Patients were randomized into two groups: Group A (n = 8) received the study emulsion Lipoplus® 20%, B. Braun Medical (50% MCT, 40% LCT, 10% fish oil (FO)); Group B (n = 8) received the control emulsion Intralipid® Fresenius Kabi (100% LCT). Lipid emulsions were administered for 12 h at a dose of 0.12 g/kg/h. We measured LTB4, TXB2, and 6-keto prostaglandin F1α values at baseline [immediately before the administration of the lipid emulsions (T-0)], at the end of the administration (T-12) and 24 hours after the beginning of the infusion (T 24) in arterial and mixed venous blood samples. Results In group A (FO) LTB4, TXB2, 6-keto prostaglandin F1α levels fell during omega-3 administration (T12). After discontinuation (T24), levels of inflammatory markers (both systemic and pulmonary) behaved erratically. In group B (LCT) all systemic and pulmonary mediators increased during lipid administration and returned to baseline levels after discontinuation, but the differences did not reach statistical significance. There was a clear interaction between the treatment in group A (fish oil) and changes in LTB4 over time. Conclusions Infusion of lipids enriched with omega-3 fatty acids produces significant short- term changes in eicosanoid values, which may be accompanied by an immunomodulatory effect. Trial registration ISRCTN63673813.

Full Text
View/download PDF

4. Cardiac tamponade as a cause of cardiac arrest in severe COVID-19 pneumonia.

Author

Ruiz-Rodríguez, Juan Carlos, Chiscano-Camon, Luis, Ruiz, Daniel, Sacanell, Judit, Argudo, Eduard, Nuvials, Francesc Xavier, Ferrer, Ricard, Camón, Luis Chiscano, Lacasa, Judit Sacanell, Serra, Eduard Argudo, and Casals, Francesc Xavier Nuvials

Subjects
*COVID-19, *CARDIAC tamponade, *CARDIAC arrest, *SARS-CoV-2, *AZITHROMYCIN, *MEDICAL societies, *DEFIBRILLATORS, *TREATMENT of cardiomyopathies, *CARDIAC tamponade treatment, *ARTIFICIAL respiration, *CARDIOPULMONARY resuscitation, *EPIDEMICS, *CARDIOMYOPATHIES, *VIRAL pneumonia, *TREATMENT effectiveness, *DISEASE progression, *DISEASE complications
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results